Opendata, web and dolomites

THUNDER

Development of the Cyclin-Dependent Kinase Inhibitor VS2-370 to Target HIV-associated Malignancies and to Purge Viral Reservoir

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THUNDER project word cloud

Explore the words cloud of the THUNDER project. It provides you a very rough idea of what is the project "THUNDER" about.

final    virostatics    men    biology    cure    similarly    decreased    induces    life    trl6    demonstrated    sides    purge    cancer    clonal    billion    apoptosis    sme    opportunity    drugs    advantages    improvement    significantly    complete    industry    expand    unlike    realizing    vivo    phase    cdk4    370    free    functional    licencing    shown    hepatitis    reservoir    savings    remissions    customer    fim    vitro    underlying    viral    tumors    suppresses    drug    first    remission    indirect    extensive    franchise    vs2    mirroring    tolerability    dependent    presently    patients    indication    reached    good    confirming    gmp    innovative    malignancies    exposure    therapy    oncology    pharma    hiv    models    periods    expansion    limits    file    tumor    biotechnology    lot    investigational    cells    capital    carry    profiles    infection    anti    anticancer    quality    strategy    profile    market    health    individuals    independently    pathogenetic    infected    antiretroviral    instrument   

Project "THUNDER" data sheet

The following table provides information about the project.

Coordinator
VIROSTATICS SRL 

Organization address
address: VIALE UMBERTO I 46
city: SASSARI
postcode: 7100
website: www.virostatics.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.virostatics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIROSTATICS SRL IT (SASSARI) coordinator 50˙000.00

Map

 Project objective

ViroStatics, operating in the biotechnology industry, is developing the innovative drug VS2-370 that targets both HIV-associated cancer and its indirect cause, the viral infection. There is no similar drug, as HIV infection and associated malignancies are presently treated independently, without realizing that they are two sides of the same underlying pathogenetic problem. VS2-370 unique anti-CDK4/6/9 profile not only suppresses HIV, but also limits clonal expansion and induces apoptosis of infected cells, with the potential to purge the viral reservoir. Unlike with currently available antiretroviral therapy (ART) this could lead to a cure of HIV infection (or functional cure, that is to allow long periods of ART-free remission), mirroring the recent success of Hepatitis C cure, and it would similarly open a multi-billion Euro market opportunity. ViroStatics strategy is to develop VS2-370 through the well established pathway of oncology drugs, then to expand the indication to the HIV cure. VS2-370 has reached TRL6 and demonstrated anticancer activity in CDK4/6/9-dependent tumors in relevant in vitro and in vivo models, it has shown good exposure/tolerability profiles, and it has been produced in a GMP lot. After confirming the interest of a Pharma Customer with franchise in Oncology and/or HIV (Phase 1) we will file an Investigational New Drug application and carry out a First in Men (FIM) study through the extensive use of systems biology (Phase 2), thus significantly increasing the value of VS2-370 before out-licencing it to the Pharma Customer. The advantages for the final users (HIV-infected individuals with associated malignancies) will be: tumor- and ART-free remissions, quality of life improvement, decreased side effects associated with ART, cost savings for the patients and the Health Systems.ViroStatics has capital to support its experienced management and to contribute in part to Phase 1 and Phase 2, but needs the SME instrument to complete the FIM study.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THUNDER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THUNDER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More